<DOC>
	<DOCNO>NCT00584012</DOCNO>
	<brief_summary>This purpose study evaluate use two medication , docetaxel lovastatin . There two phase . Subjects Phase I cancer . This phase determine high dose lovastatin docetaxel give safely well safety combine two drug effect subject 's tumor . Phase II administer lovastatin docetaxel subject breast cancer tumor .</brief_summary>
	<brief_title>A Study Proper Dosage Lovastatin Docetaxel Patients With Cancer</brief_title>
	<detailed_description>The primary objective study determine maximum tolerate dose ( MTD ) lovastatin docetaxel patient various different cancer ( phase I ) . Once MTD drug combination determine , patient breast cancer enter single cohort , phase II portion study , treat MTD dos lovastatin docetaxel .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lovastatin</mesh_term>
	<mesh_term>L 647318</mesh_term>
	<mesh_term>Dihydromevinolin</mesh_term>
	<criteria>Age &gt; 18 year age Performance Status ( ECOG ) &lt; 2 Peripheral Neuropathy &lt; grade I Signed Informed consent HematologicInclusion Absolute neutrophil count &gt; 1,500/mm3 Hemoglobin &gt; 8.0 g/dl Platelet count &gt; 100,000/mm3 . HepaticInclusion Total Bilirubin must within normal limit . Transaminases ( SGOT and/or SGPT ) may 2.5 x institutional upper limit normal ( ULN ) alkaline phosphatase &lt; ULN , alkaline phosphatase may 4 x ULN transaminases &lt; ULN . Patients may receive prior chemotherapy include treatment follow agent : anthracycline , platinum , vinorelbine , Vinca alkaloid . The patient must recover side effect prior treatment include prior druginduced peripheral neuropathy . Patients receive prior taxane therapy eligible . ( However , patient progress within 6 month receive docetaxel exclude . ) A minimum 28 day must elapse completion prior chemotherapy radiation treatment . Patients currently receive bisphosphonates bone disease allow enter trial , however bone lesion consider assessable response , assessable progression . Initiation bisphosphonate treatment trial discourage allow absence progressive disease . If bisphosphonates initiate , bone lesion assess progression . Other serious illness , would limit survival &lt; 2 month , psychiatric condition , would prevent compliance treatment informed consent . ECOG Performance Status &gt; 2 Anticipated survival &lt; 2 month Uncontrolled severe cardiovascular disease , diabetes , pulmonary disease , infection , opinion treat physician would make protocol treatment unreasonably hazardous patient . Patients `` currently active '' second malignancy nonmelanoma skin cancer . Patients consider `` currently active '' malignancy complete therapy consider physician less 30 % risk relapse within one year . Patients receive investigational agent within prior 4 week . Age &lt; 18 safety data lovastatin age range . Patients history severe hypersensitivity reaction TaxotereÂ® drug formulate polysorbate 80 . Patients receive anticancer endocrine therapy within 4 week prior registration eligible . Patients currently daily statin therapy also exclude . Patients progress within 6 month receive docetaxel eligible . Treatment antiemetic Aprepitant allow . Patients currently receive , receive Herceptin therapy within 4 week prior registration eligible . Pregnant and/or Nursing . Patients must pregnant nursing time enrollment treatment protocol . Treatment protocol would expose unborn child significant risk . Women men reproductive potential agree use effective mean birth control .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Any cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Lovastatin</keyword>
	<keyword>Docetaxel</keyword>
</DOC>